Explore ›
Finding
Finding
decline
Change in IL-6 at 1 year independently predicted incident diabetes in the metformin group only, surviving adjustment for 1-year changes in diabetes risk factors, a novel association not seen in placebo or lifestyle groups.
| Effect size | HR 1.09 |
| CI | 95% CI 1.021, 1.173 |
| Follow-up | 1 year |
| Comparator | per unit change in IL-6 at 1 year (metformin group only; no association in placebo or ILS groups) |
| Effect summary | decline; HR 1.09; CI: 95% CI 1.021, 1.173 |
| Effect modifiers | [{"modifier": "treatment group (metformin vs placebo/ILS)", "interaction_p": "heterogeneity by group present", "direction": "amplifies", "stratum_details": "IL-6 change HR 1.09 (1.021-1.173) in metformin group only; non-significant in placebo and ILS groups", "plain_language": "Rising IL-6 levels predicted diabetes only in people taking metformin, not in those doing lifestyle changes or on placebo.", "annotation_notes": "Novel metformin-emergent association. Authors speculate that metformin's effect on IL-6 is uniquely linked to its diabetes prevention mechanism independent of weight and insulin resistance changes."}] |
Connected entities
Interventions
Conditions
Outcomes
Populations
Source
PMC6456055
Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions